Program Director: Peter Nelson, M.D.; Co-directors: Janet Stanford, Ph.D., Paul Lange, M.D.
During the course of our initial SPORE grant, policies and procedures were developed for establishing a Developmental Research Program, which has been a successful component of our SPORE and continues with our 2006 renewal. On an annual basis, the program solicits innovative translational research projects in all areas of prostate cancer aimed at improving outcomes in prostate-cancer patients, and funds from three to five projects for a period of one year, with the option to extend funding for a second year if the research is successful and such an extension is justified. Applications are accepted from investigators within the SPORE participating institutions.
To fund innovative, translational research pilot projects (3-5 projects/year) aimed at improving the outcomes of prostate cancer patients.
Pilot Projects from Year 10
- Identifying the LSD1 network in prostate cancer
Joshi Alumkal, MD, Oregon Heath & Science University
- Rationale targeting of HER2 and AR to prevent emergence of MDV3100 resistance
Amina Zoubeidi, PhD, University of British Columbia
- The progesterone receptor in prostate cancer
Xuesen Dong, MD, PhD, University of British Columbia
- Urine RNA signatures for prostate cancer
Alvin Liu, PhD, University of Washington
- AR-regulated chemoresistance mechanism within the mitochondrion
David Qian, PhD, Oregon Health & Science University
- Identification of novel therapeutic agents for treating MTAP-deficient CRPC
YZ Wang, PhD, BC Cancer Agency / University of British Columbia
- Detecting high grade-specific transcripts in urine to improve active surveillance
Elahe Mostaghel, MD, PhD, Fred Hutchinson Cancer Research Center